Why Maximus Stock Is Back on Investors’ Radar

Maximus (MMS) has drawn attention after a period of weaker share performance, with the stock showing negative returns over the past week, month, past 3 months, and year to date.

At the same time, the company reports annual revenue of US$5.37b and net income of US$371.78m, supported by modest annual growth in both metrics. This gives investors concrete figures to assess against recent price moves.

Despite a weaker 90 day share price return of 21.47% and a year to date share price return of 20.91%, the 1 year total shareholder return of 4.49% shows that dividends have softened the impact of recent price weakness.

If Maximus has you reassessing your government services exposure, this can be a good moment to widen your search and check out 20 top founder-led companies

With the shares under pressure over the past year but trading below some analyst and intrinsic value estimates, the key question now is simple: is Maximus offering value, or is the market already pricing in future growth?

Most Popular Narrative: 37.8% Undervalued

Maximus is trading at $68.39 against a narrative fair value of $110, which frames the current share price as a sizable discount.

The company's ongoing investments in digital, workflow automation, and AI (notably for complex health and claims processing), along with recent inorganic growth and an expanded pipeline in federal and state markets, are laying the groundwork for sustainable earnings growth above the rate of revenue growth, as evidenced by recent margin performance and forward guidance.

Read the complete narrative. Read the complete narrative.

The fair value story centers on one main idea: steadier earnings expansion built on modest revenue growth and higher margins, supported by buybacks and a lower future P/E multiple.

Result: Fair Value of $110 (UNDERVALUED)

However, this narrative can quickly change if government agencies accelerate in-house automation and digital tools, or if large contract volumes in programs like Medicaid and SNAP reset lower.

Next Steps

With mixed signals on value, risk, and reward, the next move is yours. Check the underlying data and weigh the 5 key rewards and 1 important warning sign.

Ready to find your next idea?

You have seen what one stock can offer, but your edge comes from comparing opportunities. Do not stop here when a broader watchlist could sharpen your decisions.

• Target long term compounding potential by scanning 54 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect their financial profile.
• Strengthen your income stream by reviewing 13 dividend fortresses that focus on higher yielding companies with an emphasis on stability.
• Put capital to work in sturdier names by checking 70 resilient stocks with low risk scores designed for investors who want resilience to be a core part of their portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.